



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Anti-HIV-1 gp41 Monoclonal (50-69)
Catalog Number:	531
Lot Number:	130239
Release Category:	E
Provided:	100.5 µg affinity purified antibody at 1.50 mg/mL
Host:	Human
Titer:	ELISA: 1:1000; Western blots: 1:5; ADCC: 1:4.
Special Characteristics:	Obtained from EBV-immortalized peripheral blood mononuclear cells from HIV-seropositive individuals. The lymphoblastoid cells producing this monoclonal antibody were initially cultured in August of 1987. Reacts with a gp41 peptide spanning aa 579-613 in ELISA. Exact epitope has not been identified because this monoclonal reacts with the conformational determinant. Reactivity depends on the presence of a conformation which is maintained by an intrachain disulfide bond. Reacts with HIV lysate and a large recombinant peptide, p121, aa 560-641, but not with the short peptide aa 579-604. When this antibody was biotinylated and tested against a panel of anti-gp41 monoclonals, blocking of the binding region was confirmed. The antibody does not inhibit HIV _{IIIB} or HIV-1 _{RF} -associated cell fusion and does not neutralize HIV-1 _{IIIB} infection of AA5 cells. It mediates ADCC against IIIB and RF-infected cells, and influences IIIB infection of MT-2 target cells through complement-mediated, antibody-dependent enhancement. When conjugated to deglycosylated ricin A chain, this monoclonal kills H9 cells infected with HIV-1 isolates IIIB, LAV, SAN, BAG, and Z34.
Recommended Storage:	Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.
Contributor:	Dr. Susan Zolla-Pazner.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Isotype: IgG₁, κ chain.

References: Gorny MK, Gianakakos V, Sharpe S, Zolla-Pazner S. Generation of human monoclonal antibodies to human immunodeficiency virus. *Proc Natl Acad Sci USA* **86**:1624-1628, 1989.

Pinter A, Honnen WJ, Tilley SA, Bona C, Zaghouani H, Gorny MK, Zolla-Pazner S. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. *J Virol* **63**:2674-2679, 1989.

Till MA, Ghetie V, May R, Auerbach PC, Zolla-Pazner S, Gorny MK, Gregory T, Uhr JW, Vitetta ES. Immunoconjugates containing ricin A chain and either human anti-gp41 or C4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function. *J Acquired Immune Defic Syndr* **3**:609-614, 1990.

Xu JY, Gorny MK, Palker T, Karawowska S, Zolla-Pazner S. Epitope mapping of ten human monoclonal antibodies to gp41, the transmembrane protein of HIV-1. *J Virol* **65**:4832-4838, 1991.

Tyler DS, Stanley SD, Zolla-Pazner S, Gorny MK, Shaddock PP, Langlois AJ, Matthews TJ, Bolognesi DP, Palker TJ, Weinhold KJ. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. *J Immunol* **145**:3276-3282, 1990.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp41 Monoclonal (50-69) from Dr. Susan Zolla-Pazner." Also include the references cited above in any publications.

Patent pending. Corporate requests should be directed in writing to Dr. Susan Zolla-Pazner at the Veterans Administration Medical Center, 408 First Avenue, New York, NY 10010.

Also note that contributor will like to be informed at least two weeks before submitting a document for publication or making a public oral presentation of research results obtained from the use of this material in writing or by providing a copy of the publication document.

Recipient must not use or incorporate the reagent for commercial purposes.

Last Updated November 30, 2015

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.